Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007–2013  by Zhang, Dongmu et al.
RESEARCH ARTICLE& 2016 American Journal of Preventive Medicine. Pu
open access article under the CC BY-NC-ND licenseFrom the Ce
Co., Inc., Ken
Address c
WP97-A243,
merck.com.
0749-3797
http://dx.d
blished by Elsevier Inc. This
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U.S., 2007–2013Dongmu Zhang, PhD, Kelly Johnson, PhD, Chrisann Newransky, PhD,
Camilo J. Acosta, MD, PhD, MScIntroduction: This study aimed to assess the coverage of herpes zoster (HZ) vaccine among a large
cohort of insured individuals aged Z50 years from 2007 to 2013, and to determine the factors
associated with being vaccinated for adults aged Z60 years.
Methods: This was a retrospective, observational study using the MarketScans database
conducted in 2015. The study population was U.S. adults aged Z60 years during 20072013 and
50–59 years during 2011–2013. The claims of each eligible subject were evaluated post–index date to
assess HZ vaccine uptake. Multivariate analyses were performed to understand factors associated
with receiving HZ vaccine.
Results: A total of 6,746,476 adults aged Z60 years and 6,770,294 adults aged 50–59 years were
identiﬁed. By 2013, 1.7% of adults aged 50–59 years, 23.9% of adults aged 60–64 years, and 14.5% of
adults aged Z65 years received HZ vaccine. Adults aged Z65 years were less likely to receive HZ
vaccine than those aged 60–64 years (hazard ratio [HR]¼0.543; 95% CI¼0.539, 0.547). Adults who
were female, immunocompetent, and had more outpatient hospital, doctor ofﬁce, and pharmacy
visits were more likely to receive HZ vaccine. Adults who received inﬂuenza vaccine were more likely
to receive HZ vaccine (HR¼1.841; 95% CI¼1.830, 1.853).
Conclusions: Estimated HZ vaccine coverage is 19.5% in adults aged Z60 years, which is lower
than the Healthy People 2020 target of 30%. Providers should identify every opportunity for HZ
vaccination to assure that older adults are protected from HZ, a vaccine-preventable disease.
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oi.org/10.1016/j.amepre.2016.08.029Herpes zoster (HZ), or shingles, is a cutaneousdisease caused by the reactivation of latentvaricella zoster virus from dorsal root or cranial
nerve ganglia, present because of primary infection with
varicella, or chicken pox.1 Almost one in three individ-
uals will develop HZ in their lifetime, amounting to
1 million cases each year in the U.S.2,3 The risk of HZ
increases sharply with age, affecting up to half of all
people who live to age 85 years and causing long-term
morbidity.1
Postherpetic neuralgia is a commonly reported com-
plication,4–6 which is a chronic neuropathic pain syn-
drome caused by peripheral sensory nerve damage and
altered central nervous system signal processing. Post-
herpetic neuralgia can be severe and debilitating, and canpersist 90 or more days after rash onset caused by HZ.
Other severe complications of HZ include encephalitis,
myelitis, cranial- and peripheral-nerve palsies, and a
syndrome of delayed contralateral hemiparesis.6 HZ
has a signiﬁcant negative effect on the quality of life
and productive work life of individuals, resulting in a
signiﬁcant economic and resource burden on the U.S.
healthcare system.2,7–14is an
/licenses/by-nc-nd/4.0/).
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incidence of HZ is predicted to rise.15 Vaccination of
older adults may prevent or attenuate HZ.1 An HZ
vaccine was licensed in 2006 for prevention of HZ among
adults agedZ60 years. In March 2011, the U.S. Food and
Drug Administration approved the use of HZ vaccine in
adults aged 50–59 years. Since 2006, the Advisory
Committee on Immunization Practices (ACIP) has
recommended HZ vaccine for adults aged Z60 years.
In 2011, ACIP considered including adults aged 50–59
years in the recommendation, but declined to do so.
According to National Health Interview Survey data,
the estimated HZ vaccination coverage among adults
aged Z60 years (15.8% in 2011, 20.1% in 2012, and
24.2% in 2013) was well below the Healthy People 2020
target coverage level of 30%.16 Only one claims database
study has examined HZ vaccination coverage. Hechter
et al.17 assessed HZ vaccination coverage during 2007–
2011 in a privately insured population using Kaiser
Permanente Southern California electronic medical
record data. They estimated that HZ vaccination cover-
age reached 21.7% in 2011. They also found that the
coverage was higher among people aged 65–74 years,
women, and non-Hispanic whites.
An advantage to using claims data is that it is an
abundant and standardized source of patient information
that provides a holistic view of the patient’s interactions
with the healthcare system. The objectives of this study
were to assess the coverage of HZ vaccine among a large
cohort of insured individuals agedZ50 years from 2007
to 2013, and to determine the factors associated with
being vaccinated for adults aged Z60 years. This study
provides coverage rates among a privately insured
population, while also providing a supplement to the
vaccination rate assessed by the National Health Inter-
view Survey in 2013.16METHODS
Study Design and Data Source
This was a retrospective observational study conducted in 2015.
Two Truven Health MarketScans databases were used: the
Commercial Claims and Encounters database and the Medicare
Supplemental and Coordination of Beneﬁts database. Truven
Health provides healthcare data, analytics, and consulting services
for improving business and clinical outcomes. The commercial
database represents approximately 100 employer-sponsored pri-
vate health plans with coverage of approximately 45 million
members. The Medicare Supplemental is a database of approx-
imately 3.7 million retirees covered by their previous employers.
Both databases record patient demographic data, health plan
information, medical diagnosis/procedure codes, prescriptions,
and cost data. Each member in the databases has a unique
identiﬁer that can be used to track patient across the sites ofservice, providers, and over time. Although there is no visibility to
what parts of Medicare a person is enrolled in the Medicare
Supplemental database, the database contains the full healthcare
information (inpatient, outpatient, and pharmacy) of a retiree
from both Medicare and the employer-sponsored supplemental
plans. IRB approval was not obtained because this study was an
analysis of deidentiﬁed secondary data.
Subjects were included in this study if they: were aged Z60
years during 2007–2013 or 50–59 years during 2011–2013; and
were continuously enrolled in a health plan for at least 1 year
before the index date, which was deﬁned as January 1, 2007 or
January 1 of the calendar year when the subject turned 60 years
during 2007–2013 (or January 1, 2011 or January 1 of the calendar
year when the subject turned 50 years during 2011–2013),
whichever was latest.
Measures
HZ vaccine was identiﬁed by Current Procedural Terminology, 4th
edition, code 90736 from medical claims and National Drug Codes
00006–4963-00, 00006–4963-41, 54868–5703-00 from pharmacy
claims. The claims of each eligible subject were evaluated
postindex date to assess HZ vaccine uptake. HZ vaccine coverage
was measured as the proportion of eligible subjects who received
HZ vaccine. Both yearly HZ vaccine coverage and cumulative HZ
vaccine coverage were assessed. HZ vaccine coverage was stratiﬁed
by calendar year (2007–2013), age group (50–59, 60–64, andZ65
years), and sex (female, male).
Besides HZ vaccine coverage, factors that may be associated
with receiving HZ vaccine were examined for adults aged Z60
years, including: age group (60–64,Z65 years), immunocompro-
mised status (yes, no), sex (female, male), geographic region of
residence (Northeast, South, Midwest, West), health plan type
(HMO, Exclusive/Preferred Provider Organization, Point of Serv-
ice [POS and POS with capitation], other known), primary
provider type measured by specialty type of physicians visited
during Z70% of the subject’s doctor ofﬁce visits during the
baseline period (i.e., 1 year prior to the index date; primary care
physician, specialist, nonphysician professional, mixed primary
provider type, unknown), number of healthcare encounters during
the baseline period, including inpatient hospital visits (zero, one,
two or more); emergency department visits (zero, one, two or
more); outpatient hospital visits (zero, one to three, four to six,
seven or more); doctor ofﬁce visits (zero, one to six, seven to 12,
Z13); and pharmacy visits with prescription drugs ﬁlled (zero, one
to six, seven to 12, Z13), whether inﬂuenza vaccination was
received during the baseline period (yes, no), and rurality of
residence area (metropolitan, nonmetropolitanadjacent to a
metropolitan area, nonmetropolitannot adjacent to a metropol-
itan area, unknown).
Statistical Analysis
Descriptive statistics such as frequencies and percentages for
categorical variables and means (SDs) for continuous variables
were used to describe the characteristics of the study cohorts. HZ
vaccine coverage (%) was reported yearly by age group and by
sex, and commutatively by age group. Cox proportional
hazards model was used to analyze the factors associated with
HZ vaccination for adults aged Z60 years. Cox proportional
hazards model, a type of survival analysis method, differs fromwww.ajpmonline.org
Table 1. Characteristics of Subjects at Cohort Entry
Variable
Age 5059 years old
(n¼6,770,294)
Age 60þ years old
(n¼6,746,476)
Age, years, M (SD) 53.7 (3.1) 65.3 (8.0)
Sex
Male 3,184,929 (47.0) 3,147,621 (46.7)
Female 3,585,365 (53.0) 3,598,855 (53.3)
Immunocompromised statusa
Yes 262,505 (3.9) 377,634 (5.6)
No 6,507,789 (96.1) 6,368,842 (94.4)
Region of residence
Northeast 1,100,696 (16.2) 773,612 (11.4)
North Central 1,635,734 (24.2) 2,032,027 (30.1)
South 2,373,221 (35.1) 2,704,866 (40.1)
West 1,428,251 (21.1) 1,176,472 (17.4)
Unknown 232,392 (3.4) 59,499 (0.9)
Health plan type
HMO 916,788 (13.6) 758,986 (11.3)
EPO/PPO 4,437,128 (65.5) 3,887,887 (57.6)
POS/POS with capitation 536,851 (7.9) 543,257 (8.1)
Other known 723,851 (10.7) 1,398,043 (20.7)
Unknown 155,676 (2.3) 158,303 (2.3)
Primary provider type
PCP 1,521,399 (22.5) 1,456,929 (21.7)
Specialist 2,156,841 (31.9) 2,276,870 (33.7)
Non-physician professional 171,991 (2.5) 124,648 (1.8)
Mixed primary provider type 1,573,269 (23.2) 1,829,201 (27.1)
Unknown 1,346,794 (19.9) 1,058,828 (15.7)
No. of inpatient hospital visits
0 6,451,033 (95.3) 6,078,242 (90.1)
1þ 319,261 (4.7) 668,234 (9.9)
No. of outpatient hospital visits
0 3,400,144 (50.3) 2,837,026 (42.0)
1–3 2,438,684 (36.0) 2,584,403 (38.3)
4–6 557,424 (8.2) 733,507 (10.9)
7þ 374,042 (5.5) 591,540 (8.8)
No. of emergency department visits
0 6,676,838 (98.6) 6,626,194 (98.2)
1þ 93,456 (1.4) 120,282 (1.8)
No. of doctor ofﬁce visits
0 1,144,513 (16.8) 813,391 (12.0)
1–6 3,246,710 (48.0) 2,803,547 (41.6)
7–12 1,244,555 (18.4) 1,566,497 (23.2)
13þ 1,134,516 (16.8) 1,563,041 (23.2)
No. of pharmacy visits with prescription drugs ﬁlled
0 2,502,390 (37.0) 1,880,256 (27.8)
1–6 1,561,574 (23.0) 1,157,582 (17.2)
7–12 992,244 (14.7) 1,161,213 (17.2)
13þ 1,714,086 (25.3) 2,547,425 (37.8)
Note: Data are n (%) unless otherwise noted.
aImmunocompromised conditions include: hematologic malignancy, HIV, disorders involving the immune
mechanism, aplastic anemia and other bone marrow failure syndromes, organ transplantation, hematopoietic
stem cell transplantation, and treatments of chemotherapy, immunotherapy, radiation therapy, tumor necrosis
factor inhibitors, protease inhibitors, reverse transcriptase inhibitors, azathioprine, cyclosporine, or tacrolimus.
EPO, exclusive provider organization; PPO, preferred provider organization; POS, point of service; PCP,
primary care physician, including family practice and internal medicine.
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January 2017logistic regression by assessing a
rate instead of a proportion. It
models the number of subjects
receiving HZ vaccine per eligible
population per unit time. The
follow-up time was censored at
HZ vaccination, the end of con-
tinuous health plan enrollment,
or the end of the study period
(December 31, 2014), whichever
was the earliest. All statistical
analyses were performed using
SAS, version 9.3.RESULTS
A total of 6,746,476 eligible
adults aged Z60 years in
2007–2013 and 6,770,294
eligible adults aged 50–59
years in 2011–2013 were
identiﬁed. Mean age in
adults Z60 years old was
65.3 (SD¼8.0) years and
mean age in adults 50–59
years old was 53.7 (SD¼3.1)
years. About 53% were
female in both cohorts
(Table 1).
Coverage for HZ vaccine
increased from 2007 to 2013
(Figure 1). The vaccination
rate was higher in adults
aged 60–64 years and
women versus the compara-
tors across all study years. By
2013, 1.7% of adults aged
50–59 years, 23.9% of adults
aged 60–64 years, and 14.5%
of adults aged Z65 years
received HZ vaccine
(Appendix Figure 1, avail-
able online). When adults
aged 60–64 years and Z65
years were combined, HZ
vaccine coverage in adults
aged Z60 years was 19.5%
(Figure 2).
Table 2 presents the fac-
tors associated with receiv-
ing HZ vaccination in adults
Z60 years. Adults agedZ65
years were less likely to
receive HZ vaccine than
Figure 1. Yearly HZ vaccine coverage by age group and sex,
2007–2013.
Note: Adults 50–59 years old only have HZ vaccination rates from
2011–2013.
HZ, herpes zoster.
Zhang et al / Am J Prev Med 2017;52(1):e17–e23e20those aged 60–64 years (hazard ratio [HR]¼0.543, 95%
CI¼0.540, 0.547). Women were more likely to receive
HZ vaccine than men (HR¼1.106, 95% CI¼1.100,
1.112). Immunocompromised subjects were less likely
to receive HZ vaccine than immunocompetent subjects
(HR¼0.888, 95% CI¼0.877, 0.898). Subjects who
received inﬂuenza vaccine were more likely to receive
HZ vaccine (HR¼1.841, 95% CI¼1.830, 1.853). Adults
with more outpatient hospital visits, more doctor ofﬁce
visits, and more pharmacy visits were more likely to
receive the vaccine. However, those with more inpatient
hospital visits and more emergency department visits
were less likely to receive the vaccine. Adults who lived in
the South and in the rural areas were less likely to receive
HZ vaccine. Adults with Exclusive/Preferred Provider
Organization or POS health plan types were slightly
more likely to receive HZ vaccine than those with a HMO
health plan type. Adults with a primary provider other
than a primary care physician were more likely to receiveFigure 2. Cumulative HZ vaccine coverage by age group:
50–59 and 60þ years, 2007–2013.
HZ, herpes zoster.the vaccine than adults with a primary care physician as
their primary provider.
DISCUSSION
This study found that HZ vaccine coverage improved
from 2007 to 2013. By 2013, 19.5% of adults aged Z60
years (23.9% of adults aged 60–64 years and 14.5% of
adults aged Z65 years) received an HZ vaccine. This
increasing trend may be a result of several factors driven
by greater acceptance of the 2006 ACIP recommenda-
tion. However, these rates are still lower than the 30%
target of Healthy People 2020.
The overall HZ vaccine coverage estimate from this
study, 19.5% for adults aged Z60 years in 2013, is
somewhat lower than the National Health Interview
Survey estimate of 24.2% using national survey data in
2013 and Hechter and colleagues’17 estimate of 21.7%
using electronic health records from an MCO in 2011.
This could be due to a difference in methodology and the
use of different types of data sources (i.e., claims database
from multiple payers versus survey, including uninsured
populations versus electronic medical record database
from a single payer).
Hechter et al.17 found that HZ vaccine coverage was
higher among people aged 65–74 years, women, and
non-Hispanic whites. The multivariate analysis in this
study also suggested that women were more likely to
receive HZ vaccine than men. However, this study
showed that adults aged Z65 years were less likely to
receive HZ vaccine compared with those aged 60–64
years whose health beneﬁts should, in principle, cover
full cost of vaccines. This may be due to the high
copayment for Medicare eligible subjects or complicated
provider reimbursement.18,19 This study also found that
immunocompromised adults were less likely to receive
HZ vaccine than immunocompetent subjects, reﬂecting
the prescribed indication. Interestingly, this study found
that adults who received inﬂuenza vaccine were more
likely to receive HZ vaccine. This may be because patients
who had inﬂuenza vaccine were more cautious about
their health or generally had a higher level of perceived
risk in relation to illness. Research has shown that HZ
vaccine is well tolerated and the antibody response is
similar when administered concomitantly or sequentially
with the inﬂuenza vaccine.20 Similar ﬁndings of the
association between inﬂuenza vaccination and pneumo-
coccal vaccination have also been noted.21–23 In addition,
this study found that adults with more outpatient
hospital visits, more doctor ofﬁce visits, and more
pharmacy visits with prescription drugs ﬁlled were more
likely to receive the vaccine. This could be because
patients with more healthcare encounters were morewww.ajpmonline.org
Table 2. Factors Associated with HZ Vaccination in Adults 60 Years and Older (n¼6,529,070)a
Variable HR (95% CI) p-value
Age
60–64 years ref
65þ years 0.543 (0.540, 0.547) o0.0001
Sex
Male ref
Female 1.106 (1.100, 1.112) o0.0001
Immunocompromised status
No ref
Yes 0.888 (0.877, 0.898) o0.0001
Region of residence
North central ref
Northeast 1.005 (0.995, 1.014) 0.3321
South 0.958 (0.952, 0.965) o0.0001
West 1.381 (1.371, 1.392) o0.0001
Health plan type
HMO ref
EPO/PPO 1.034 (1.026, 1.042) o0.0001
POS/POS with capitation 1.032 (1.021, 1.044) o0.0001
Other known 0.963 (0.953, 0.972) o0.0001
Primary provider type
PCP ref
Specialist 1.050 (1.042, 1.058) o0.0001
Non-physician professional 1.101 (1.080, 1.123) o0.0001
Mixed primary provider type 1.205 (1.195, 1.214) o0.0001
Unknown 1.159 (1.139, 1.180) o0.0001
No. of inpatient hospital visits
0 ref
1þ 0.693 (0.685, 0.701) o0.0001
No. of outpatient hospital visits
0 ref
1–3 1.207 (1.199, 1.215) o0.0001
4–6 1.201 (1.190, 1.212) o0.0001
7þ 1.194 (1.181, 1.207) o0.0001
No. of emergency department visits
0 ref
1þ 0.941 (0.917, 0.965) o0.0001
No. of doctor ofﬁce visits
0 ref
1–6 1.929 (1.890, 1.970) o0.0001
7–12 2.147 (2.101, 2.193) o0.0001
13þ 2.307 (2.257, 2.358) o0.0001
No. of pharmacy visits with prescription drugs ﬁlled
0 ref
1–6 1.444 (1.431, 1.458) o0.0001
7–12 1.580 (1.566, 1.595) o0.0001
13þ 1.448 (1.436, 1.461) o0.0001
Inﬂuenza vaccine
No ref
Yes 1.841 (1.830, 1.853) o0.0001
(continued on next page)
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Table 2. Factors Associated with HZ Vaccination in Adults 60 Years and Older (n¼6,529,070)
a (continued)
Variable HR (95% CI) p-value
Rurality
Metro ref
Nonmetro, adjacent to a metro area 0.805 (0.797, 0.814) o0.0001
Nonmetro, not adjacent to a metro area 0.882 (0.869, 0.895) o0.0001
Unknown 2.783 (2.764, 2.803) o0.0001
Note: Boldface indicates statistical signiﬁcance (po0.0001).
aSubjects with unknown region of residence or unknown health plan type were removed from the multivariate analysis.
HZ, herpes zoster; EPO, exclusive provider organization; PPO, preferred provider organization; POS, point of service; PCP, primary care physician,
including family practice and internal medicine.
Zhang et al / Am J Prev Med 2017;52(1):e17–e23e22likely to be informed about the vaccine or be more aware
of the recommendation for the vaccine. By contrast, this
study found that adults with more inpatient hospital
visits and more emergency department visits were less
likely to receive the vaccine. These people may forgo
the HZ vaccine, owing to other severe illness or contra-
indication. Finally, this study found that adults who
lived in the South and in the rural areas of the U.S. were
less likely to receive HZ vaccine. This may be because of
lack of access to care or to the vaccine. In the study
cohort, residents from rural areas had fewer doctor ofﬁce
visits than residents from a metropolitan area
(mean¼8.0, 8.2, and 9.4 for residents from nonmetro-
politannot adjacent to a metropolitan area, nonme-
tropolitanadjacent to a metropolitan area, and
metropolitan area, respectively). Further research is
needed in this regard.
The sample used to analyze factors associated with HZ
vaccine has more than 6.5 million subjects. Such a large
sample is more representative of the population, limiting
the inﬂuence of outliers or extreme values, and having
statistical power to detect signiﬁcant factors. However, with
such a large sample, trivially small effects can be found
statistically signiﬁcant. For example, compared with HMO
health plan type, Exclusive/Preferred Provider Organiza-
tion (HR¼1.034) and POS (HR¼1.032) health plan types
were statistically signiﬁcant. However, as the effects are so
small, they may not have practical signiﬁcance.
By 2013, only 1.7% of adults aged 50–59 years received
the HZ vaccine. Even though the U.S. Food and Drug
Administration approved the indication of the HZ
vaccine in adults aged 50–59 years in 2011, ACIP did
not give the universal recommendation to adults aged
50–59 years. For this reason, adults aged 50–59 years may
not be aware of the HZ vaccine, healthcare providers may
be reluctant to give the vaccine, and the insurance may
not cover the vaccination. Further studies are needed to
ﬁnd the actual reasons for low HZ vaccination rate for
adults aged 50–59 years. In the U.S., adults in this agegroup are most likely still working; HZ has the potential
to cause these individuals to incur work and productivity
loss. In fact, European studies using patient-reported
outcomes indicate that among individuals aged 50–59
years, HZ episodes interfere with work and cause
absenteeism due to healthcare visits, pain, discomfort,
and inability to concentrate.24,25
Limitations
Several limitations inherent to administrative claims data
apply to this study. First, HZ vaccines that were not
submitted for insurance reimbursement or were received
outside the network will not be captured. Furthermore, the
study cohort consists of U.S. privately insured population,
and therefore generalization may not be made beyond this
population. Third, other factors that were examined in
previous survey studies, such as race/ethnicity, SES,
awareness of the vaccine recommendations, knowledge
of HZ, perceived need, and provider recommendation, are
not available in claims data. Finally, immunocompro-
mised status is based only on claims database information
(without any medical record review). This is likely to result
in some misclassiﬁcation of immunocompromised status.
CONCLUSIONS
The estimated HZ vaccine coverage is 19.5% in adults
aged Z60 years, which is lower than the 30% target of
Healthy People 2020. It is important for providers to
identify every opportunity for HZ vaccination and to
assure that older adults are protected from HZ. Specif-
ically, efforts should be made to encourage HZ vacci-
nation of people aged Z65 years when giving other
immunizations, such as inﬂuenza.ACKNOWLEDGMENTS
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